STOCKS TO BUY: We have identified several stocks that can potentially TRIPLE. Learn more!

Tony Pelz

Contributor to TheStreet

Email This Author

Tony Pelz was a trader on a major European bank's proprietary trading desk, responsible for a portfolio with limits of more than $200 million. Prior to proprietary trading, Pelz worked with several global investment banks in roles ranging from corporate finance, M&A to credit and business development. He is author of The Biotech Trader Handbook, 2nd Edition, co-founder of the small-cap biotech research and trading site Chimera Research Group and operator of PelzOptions.com. Pelz currently resides in Denver, Colorado where he trades for his own account.

Tony Pelz
By This Author:
Page 2 of 2
Next »
Article

How To Trade Peregrine Pharma's Lung Cancer Fiasco

By Tony Pelz

Options expert Tony Pelz outlines a short-biased trade to play Peregrine's decline.

Related Topics: Biotech | Drugs | Health Care

08:00AM 10/01/12

Article

Options 'Flow' Foretold Questcor Plunge

By Tony Pelz

Tony Pelz shows investors how to monitor unusual options trades to manage risk.

Related Topics: Biotech | Drugs | Health Care

07:23AM 09/24/12

Article

Sarepta Therapeutics: A High-Octane Options Trade

By Tony Pelz

Tony Pelz offers an options trading strategy for investing in Sarepta and next month's eteplirsen data presentation.

Related Topics: Biotech | Drugs | Health Care

09:33AM 09/17/12

Article

Trading Biotech With Options: Exelixis

By Tony Pelz

Tony Pelz debuts a new column focused on using options to invest and trade in biotech stocks.

Related Topics: Biotech | Drugs | Health Care

11:54AM 09/10/12

Page 2 of 2
Next »

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
TRY IT FREE

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
TRY IT FREE
New! $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
TRY IT FREE

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
TRY IT FREE

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
TRY IT FREE

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass + 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
TRY IT FREE

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
DOW 15,298.03 -20.20 -0.13%
NASDAQ 3,475.76 -6.42 -0.18%
S&P 500 1,649.23 -2.58 -0.16%
US 10 Yr 2.209% +0.027

Brokerage Partners
Advertising Partners

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

We respect your privacy.
Manage Newsletters

Top Rated Stocks Top Rated Funds Top Rated ETFs